vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
imlygic
amgen europe b.v. - talimogene laherparepvec - melanoma - antineoplastic agents - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.
beovu
novartis europharm limited - brolucizumab - wet macular degeneration - ophthalmologicals - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).
cimeldine 400 mg film-coated tablets
clonmel healthcare ltd - cimetidine - film-coated tablet - 400 milligram(s) - h2-receptor antagonists; cimetidine
torisel concentrate for injection 25mgml
pfizer private limited - (drug product) temsirolimus - injection, solution, concentrate - 25.0mg/ml - (drug product) temsirolimus 25.0mg/ml
nexavar tablet 200 mg
bayer (south east asia) pte ltd - sorafenib tosylate 274.0 mg eqv sorafenib - tablet, film coated - 200 mg - sorafenib tosylate 274.0 mg eqv sorafenib 200 mg
aircort pressurised inhalation suspension 200mcg/dose
italchimici s.p.a. via pontina n.5, km 29 00071 pomezia, rome, italy - budesonide - pressurised inhalation, suspension - budesonide 40 mg - drugs for obstructive airway diseases
eylea
bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).
torisel
pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastic agents - renal-cell carcinomatorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (rcc) who have at least three of six prognostic risk factors.mantle-cell lymphomatorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (mcl).
lucentis 2.3mg0.23ml solution for injection vials
novartis pharmaceuticals uk ltd - ranibizumab - solution for injection - 10mg/1ml